Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
Public ClinicalTrials.gov record NCT01634152. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Children (6 to 11 Years Old) With Severe Persistent Asthma
Study identification
- NCT ID
- NCT01634152
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Enrollment
- 401 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Tiotropium high dose Drug
- Tiotropium low dose mcg Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 11 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 2012
- Primary completion
- Apr 30, 2015
- Completion
- Apr 30, 2015
- Last update posted
- Jan 28, 2016
2012 – 2015
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.446.01014 Boehringer Ingelheim Investigational Site | Rolling Hills Estates | California | — | — |
| 205.446.01011 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 205.446.01003 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 205.446.01009 Boehringer Ingelheim Investigational Site | Columbia | Missouri | — | — |
| 205.446.01005 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 205.446.01010 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 205.446.01004 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.446.01002 Boehringer Ingelheim Investigational Site | North Charleston | South Carolina | — | — |
| 205.446.01012 Boehringer Ingelheim Investigational Site | Arlington | Texas | — | — |
| 205.446.01013 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 84 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01634152, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 28, 2016 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01634152 live on ClinicalTrials.gov.